BSEConcord Drugs LtdMinimalNeutral
Announced Tue, 20 Jan · 13:16 IST

Certificate under Reg 74(5) of SEBI (DP) regulations

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Concord Drugs Ltd has submitted to BSE a certificate from its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, under SEBI Regulation 74(5). The certificate covers the quarter from 1 October 2025 to 31 December 2025 and confirms that all share certificates received from depository participants were dematerialized, cancelled, and records updated within the required 15-day timeline. The filing was signed by Managing Director Nagi Reddy Seelam. This is a standard quarterly compliance requirement with no operational or financial details disclosed.

Likely market impact

This is a routine regulatory compliance filing with no material impact on the company's business, financials, or stock price. It simply confirms that dematerialization requests during the October–December 2025 quarter were processed on time.